2027, FDA Approval and Licensing - Drug Discovery Digest

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

MAY 4, 2021

RE47,739 for Ibrance by more than four years until March 2027. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Vaccine

Vaccine Production FDA Clinical Trials

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

FEBRUARY 11, 2024

Few would oppose FDA-approved marijuana-derived medications if marijuana compounds are found to have medical value; the National Institute of Health should continue to fund research on any potential medical value of marijuana and on the harms of highly potent products.

Regulations

Regulations Production FDA Approval Drugs

Drug Discovery Digest

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

Webinars

Stay Connected